IMNM

Immunome, Inc.

IMNM · CIK 1472012 · Annual (10-K) · Last 5 years

Financial Trends

Revenue$9M
20202024
Net Income−$293M
20202024
Operating CF−$111M
20202024
Free Cash Flow−$118M
20202024

Income Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕
Revenue$0.0B$0.0B———
Cost of Revenue—————
Gross Profit—————
R&D Expense$0.1B$0.0B$0.0B$0.0B$0.0B
SG&A Expense—————
Operating Income$-0.3B$-0.1B$-0.0B$-0.0B$-0.0B
Net Income$-0.3B$-0.1B$-0.0B$-0.0B$-0.0B
EPS (Basic)$-5.00$-5.38$-3.09$-2.14—
EPS (Diluted)$-5.00$-5.38$-3.09$-2.14—

Balance Sheet

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕
Total Assets$0.2B$0.1B$0.0B$0.1B$0.0B
Current Assets$0.2B$0.1B$0.0B$0.1B$0.0B
Cash & Equivalents$0.1B$0.1B$0.0B$0.0B$0.0B
Total Liabilities$0.1B$0.0B$0.0B$0.0B$0.0B
Current Liabilities$0.1B$0.0B$0.0B$0.0B$0.0B
Stockholders' Equity$0.2B$0.1B$0.0B$0.0B$0.0B

Cash Flow Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕
Operating Cash Flow$-0.1B$-0.0B$-0.0B$-0.0B$-0.0B
Investing Cash Flow$-0.1B$-0.0B$-0.0B$-0.0B$-0.0B
Capital Expenditures$0.0B$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$0.2B$0.1B$0.0B$0.0B$0.0B
← Companies